PT2858496T - Óleos com atividade anti-inflamatória que contêm mediadores especializados na pró-resolução naturais e os seus percursores - Google Patents
Óleos com atividade anti-inflamatória que contêm mediadores especializados na pró-resolução naturais e os seus percursoresInfo
- Publication number
- PT2858496T PT2858496T PT137880589T PT13788058T PT2858496T PT 2858496 T PT2858496 T PT 2858496T PT 137880589 T PT137880589 T PT 137880589T PT 13788058 T PT13788058 T PT 13788058T PT 2858496 T PT2858496 T PT 2858496T
- Authority
- PT
- Portugal
- Prior art keywords
- precursors
- oils
- inflammatory activity
- containing natural
- activity containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261645281P | 2012-05-10 | 2012-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2858496T true PT2858496T (pt) | 2023-07-20 |
Family
ID=49551457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT137880589T PT2858496T (pt) | 2012-05-10 | 2013-05-09 | Óleos com atividade anti-inflamatória que contêm mediadores especializados na pró-resolução naturais e os seus percursores |
Country Status (12)
Country | Link |
---|---|
US (6) | US10568858B2 (pt) |
EP (2) | EP4205546A1 (pt) |
JP (2) | JP6370775B2 (pt) |
CN (3) | CN110478342A (pt) |
AU (1) | AU2013259503B2 (pt) |
CA (1) | CA2873055C (pt) |
DK (1) | DK2858496T3 (pt) |
ES (1) | ES2946109T3 (pt) |
NZ (1) | NZ702325A (pt) |
PL (1) | PL2858496T3 (pt) |
PT (1) | PT2858496T (pt) |
WO (1) | WO2013170006A2 (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
JP6370775B2 (ja) * | 2012-05-10 | 2018-08-08 | ソルテックス エヌエー エルエルシー | 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油 |
GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
EP3892608A1 (en) | 2013-05-30 | 2021-10-13 | The Brigham and Women's Hospital, Inc. | Novel n-3 immunoresolvents: structures and actions |
EP3546446A1 (en) | 2013-11-15 | 2019-10-02 | DS Biopharma Limited | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |
SG11201605601UA (en) * | 2014-01-10 | 2016-08-30 | Mehar Manku | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
JP6604529B2 (ja) * | 2014-01-29 | 2019-11-13 | 岩手県 | ヒドロキシエイコサペンタエン酸の取得方法 |
JP6315536B2 (ja) * | 2014-01-29 | 2018-04-25 | 岩手県 | Ppar活性化剤 |
CN106687113B (zh) | 2014-06-06 | 2021-09-03 | 海洋原料公司 | ω-3组合物、剂型及使用方法 |
MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
WO2016113635A1 (en) * | 2015-01-16 | 2016-07-21 | Dignity Sciences Limited | Compositions comprising 15-hepe and methods of using the same |
EP3256438A4 (en) * | 2015-02-09 | 2018-10-31 | The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases |
EP3267990A4 (en) | 2015-03-10 | 2018-09-05 | ELC Management LLC | Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways |
EP3325094B1 (en) | 2015-07-21 | 2021-01-06 | Afimmune Limited | Compositions comprising 15(s)-hepe for use in sensitizing cancer cells to radiation therapy |
WO2017041094A1 (en) * | 2015-09-03 | 2017-03-09 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same |
ES2607715B1 (es) * | 2015-10-01 | 2018-01-17 | Solutex Na, Lcc | Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa |
SG11201805149XA (en) | 2015-12-18 | 2018-07-30 | Afimmune Ltd | Compositions comprising 15-hepe and methods of using the same |
EP3795179A1 (en) | 2016-06-03 | 2021-03-24 | Thetis Pharmaceuticals LLC | Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation |
IL268144B2 (en) * | 2017-01-18 | 2024-05-01 | Univ Barcelona Autonoma | Targeted Segregation Assisted Lipid Mediators for Use in the Treatment of Neurodegenerative and/or Autoimmune Diseases |
US11583511B2 (en) | 2017-07-20 | 2023-02-21 | Universitat Autonoma De Barcelona | Maresins for use in the treatment of CNS injuries |
KR101981534B1 (ko) * | 2017-09-01 | 2019-05-23 | (주)솔빛피앤에프 | 프로텍틴 dx를 유효성분으로 함유하는 고지혈증 또는 지방간 질환 예방 또는 치료용 조성물 |
KR102003153B1 (ko) * | 2018-01-17 | 2019-07-23 | 연세대학교 산학협력단 | 레졸빈 d2를 유효성분으로 함유하는 피부 염증 치료용 조성물 |
EP3792351A4 (en) * | 2018-04-16 | 2022-01-19 | Korea Research Institute of Bioscience and Biotechnology | PROCESS FOR THE PREPARATION OF MULTI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS |
CN108578398A (zh) * | 2018-06-11 | 2018-09-28 | 温州医科大学 | 巨噬素在制备预防或治疗类风湿性关节炎的药物中的应用 |
NO345574B1 (en) * | 2018-06-19 | 2021-04-26 | Epax Norway As | Composition for treatment of dry eye disease and meibomianitis |
WO2019243887A1 (en) | 2018-06-22 | 2019-12-26 | Ambiotis | Method for restoration of the natural capacity of the body to end inflammation by personalization of the food supplementation and objectification of its effect |
CA3114750A1 (en) | 2018-10-09 | 2020-04-16 | University Of Rochester | Treatment of vulvovaginal disorders |
KR102673270B1 (ko) * | 2018-10-15 | 2024-06-07 | (주)아모레퍼시픽 | 피부장벽 강화용 조성물 |
US11400057B2 (en) | 2018-10-19 | 2022-08-02 | University Of Rochester | Treatment of vulvar pain |
KR20200046458A (ko) * | 2018-10-24 | 2020-05-07 | (주)아모레퍼시픽 | 피부장벽 강화용 조성물 |
EP3886832A1 (en) * | 2018-11-30 | 2021-10-06 | Evonik Operations GmbH | Preparation for use to increase the formation of one or more specialized pro-resolving lipid mediators (spm) |
US20220308071A1 (en) * | 2019-06-13 | 2022-09-29 | The Regents Of The University Of California | Methods and compositions for determination of liver fibrosis |
CN110420224A (zh) * | 2019-07-25 | 2019-11-08 | 江苏华豚药业有限公司 | 河豚肝油皂化物的应用及其制备方法 |
CN114144192A (zh) * | 2019-08-01 | 2022-03-04 | 赢创运营有限公司 | 包含ω-3脂肪酸盐和来自乳香属物种的胶树脂提取物的制剂 |
US11607623B2 (en) | 2019-08-08 | 2023-03-21 | Cornerstone Technologies Llc | Dynamic interface system and its application in supercritical fluid extraction and chromatography |
JP7349569B2 (ja) * | 2019-12-06 | 2023-09-22 | コーロン インダストリーズ インク | 多価不飽和脂肪酸のモノ-ヒドロキシまたはジ-ヒドロキシ誘導体、その生産方法およびその用途 |
KR102256823B1 (ko) * | 2019-12-06 | 2021-05-26 | 한국생명공학연구원 | 도코사헥사노엔산 유도체를 함유하는 주름 개선, 아토피피부염 개선 및 피부 장벽 강화용 복합 조성물 |
JP2023504205A (ja) * | 2019-12-09 | 2023-02-01 | ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ | 角膜病変の治療のための生体分子 |
WO2022013478A1 (es) | 2020-07-17 | 2022-01-20 | Solutex Gc, S. L. | Método diagnóstico y compuestos para el tratamiento de infecciones causadas por un patógeno |
WO2022049168A1 (en) * | 2020-09-04 | 2022-03-10 | Dsm Ip Assets B.V. | 17(s)-hdpa for metabolic-syndrome related disorders |
EP4255412A1 (en) | 2020-12-04 | 2023-10-11 | Chemo Research, S.L. | Specialized pro-resolving lipid mediators for treating pcos |
KR102662544B1 (ko) * | 2021-10-19 | 2024-05-03 | 서울대학교산학협력단 | 참문어 추출물을 유효성분으로 포함하는 만성 폐쇄성 폐질환 예방 또는 치료용 약학적 조성물 |
WO2023180569A1 (en) | 2022-03-25 | 2023-09-28 | Chemo Research , S.L. | Specialized pro-resolving lipid mediators for treating long covid-19 |
CN115466776A (zh) * | 2022-09-26 | 2022-12-13 | 中国医学科学院基础医学研究所 | 检测嗜酸性粒细胞的试剂、嗜酸性粒细胞及其胞质内容物和羟基二十二碳六烯酸的应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JPH01169354A (ja) * | 1987-12-25 | 1989-07-04 | Hitachi Ltd | 超臨界炭酸ガス抽出物の分取方法 |
US4966876A (en) | 1989-08-22 | 1990-10-30 | Viswanatha Sankaran | Transesterification of triglycerides |
US5133902A (en) | 1989-08-22 | 1992-07-28 | Viswanatha Sankaran | Transesterification of triglycerides |
IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
KR100234947B1 (ko) | 1997-06-05 | 1999-12-15 | 이형도 | 멀티 탭 고주파 모듈레이터 |
KR100587551B1 (ko) | 1997-12-10 | 2006-06-08 | 싸이클로스포린 테라퓨틱스 리미티드 | 오메가-3 지방산 오일을 함유하는 약학 조성물 |
JP4175698B2 (ja) * | 1998-06-19 | 2008-11-05 | サントリー株式会社 | 新規なトリグリセリド及びそれを含む組成物 |
ATE504557T1 (de) | 2000-02-16 | 2011-04-15 | Brigham & Womens Hospital | Aspirin-ausgelöste lipidmediatoren |
US20040176451A1 (en) * | 2001-06-18 | 2004-09-09 | Tadakazu Tamai | Pparg agonistic medicinal compositions |
US7759395B2 (en) * | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
AU2003284617A1 (en) | 2002-11-22 | 2004-06-18 | Nippon Suisan Kaisha, Ltd. | Composition containing organic substance having double bond with improved oxidation stability |
JP4280158B2 (ja) | 2002-12-27 | 2009-06-17 | 富士フイルム株式会社 | ドコサヘキサエン酸生産能を有する微生物及びその利用 |
AU2005306320B2 (en) * | 2004-11-19 | 2011-09-08 | Martek Biosciences Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
US20090318394A1 (en) | 2004-11-19 | 2009-12-24 | Julie Nauroth | Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same |
JP2009051732A (ja) * | 2005-12-13 | 2009-03-12 | Meiji Seika Kaisha Ltd | Pparリガンド活性を有する組成物 |
CN101663031A (zh) * | 2007-02-20 | 2010-03-03 | 马泰克生物科学公司 | 来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法 |
CN101796014A (zh) * | 2007-06-29 | 2010-08-04 | 马泰克生物科学公司 | 多不饱和脂肪酸酯的制备和纯化 |
CN103120225A (zh) | 2007-08-31 | 2013-05-29 | 马太克生物科学公司 | 含多不饱和脂肪酸的固体脂肪组合物及其制备与应用 |
ES2792676T3 (es) * | 2008-09-16 | 2020-11-11 | Brigham & Womens Hospital Inc | Compuestos del ácido 14-hidroxi-docosahexaenoico |
JP5523439B2 (ja) | 2009-02-20 | 2014-06-18 | 国立大学法人 東京大学 | 新規抗炎症性化合物 |
US20110071090A1 (en) | 2009-03-11 | 2011-03-24 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle |
CL2009001343A1 (es) * | 2009-06-02 | 2009-07-10 | Golden Omega S A | Proceso de obtencion concentrado de esteres de epa y dha a partir de aceite marino, que comprende agregar al aceite alcali y agua a menos de 100 grados celsius, agregar solvente, separar fase de refinado, agregar acido, separar la fase no acuosa y agregar alcohol y un catalizador a menos de 150 grados celsius, desolventilizar y destilar. |
US8479921B2 (en) | 2009-12-09 | 2013-07-09 | Amcor Flexibles, Inc. | Child resistant blister package |
US20110178105A1 (en) | 2010-01-15 | 2011-07-21 | E.I. Du Pont De Nemours And Company | Clinical benefits of eicosapentaenoic acid in humans |
US9238634B2 (en) | 2010-08-19 | 2016-01-19 | The University Of Tokyo | Anti-inflammatory metabolite derived from omega-3-type fatty acid |
US8865685B2 (en) | 2011-06-30 | 2014-10-21 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
EP2798066A4 (en) | 2011-12-27 | 2016-02-24 | Commw Scient Ind Res Org | PROCESSES FOR PRODUCING LIPIDS |
JP6370775B2 (ja) | 2012-05-10 | 2018-08-08 | ソルテックス エヌエー エルエルシー | 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油 |
KR20160025015A (ko) | 2013-06-27 | 2016-03-07 | 스마트피쉬 에이에스 | 염증의 치료를 위한 피쉬 오일 및 주스를 포함하는 조성물의 사용 |
SG11201605601UA (en) | 2014-01-10 | 2016-08-30 | Mehar Manku | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
WO2017041094A1 (en) | 2015-09-03 | 2017-03-09 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same |
-
2013
- 2013-05-09 JP JP2015511694A patent/JP6370775B2/ja active Active
- 2013-05-09 EP EP23157714.9A patent/EP4205546A1/en active Pending
- 2013-05-09 CN CN201910864506.XA patent/CN110478342A/zh active Pending
- 2013-05-09 PT PT137880589T patent/PT2858496T/pt unknown
- 2013-05-09 ES ES13788058T patent/ES2946109T3/es active Active
- 2013-05-09 EP EP13788058.9A patent/EP2858496B9/en active Active
- 2013-05-09 AU AU2013259503A patent/AU2013259503B2/en active Active
- 2013-05-09 US US14/400,198 patent/US10568858B2/en active Active
- 2013-05-09 CN CN202310172271.4A patent/CN116173001A/zh active Pending
- 2013-05-09 WO PCT/US2013/040314 patent/WO2013170006A2/en active Application Filing
- 2013-05-09 CA CA2873055A patent/CA2873055C/en active Active
- 2013-05-09 CN CN201380036376.1A patent/CN104684389A/zh active Pending
- 2013-05-09 NZ NZ702325A patent/NZ702325A/en unknown
- 2013-05-09 PL PL13788058.9T patent/PL2858496T3/pl unknown
- 2013-05-09 DK DK13788058.9T patent/DK2858496T3/da active
-
2018
- 2018-03-26 US US15/935,913 patent/US20180271818A1/en not_active Abandoned
- 2018-07-11 JP JP2018131272A patent/JP6821626B2/ja active Active
-
2019
- 2019-03-08 US US16/297,240 patent/US11077083B2/en active Active
-
2020
- 2020-05-26 US US16/882,910 patent/US11285126B2/en active Active
-
2021
- 2021-02-01 US US17/163,722 patent/US11077084B2/en active Active
-
2022
- 2022-02-22 US US17/677,158 patent/US11865096B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2858496T3 (pl) | Oleje o działaniu przeciwzapalnym zawierające naturalne wyspecjalizowane mediatory prorozdzielcze i ich prekursory | |
HK1216322A1 (zh) | 組糖基轉移酶及其應用 | |
HK1202545A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
IL234628A0 (en) | Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs | |
ZA201404929B (en) | Compositions and methods for surface treatment with lipases | |
EP2929874A4 (en) | COSMETIC ADDITIVE AND COSMETIC PRODUCT CONTAINING SAME | |
HK1205759A1 (en) | Treatment of biomass | |
EP2800590A4 (en) | DIVIDED AND SIDE-BASED CATHETER DEVICES | |
HK1210585A1 (en) | Alpha-1-microglobulin for use in the treatment of mitochondria- related diseases -1 | |
EP2873868A4 (en) | PUMP AND PUMP FIXING STRUCTURE | |
EP2697386A4 (en) | DESIGN AND USE OF PEPDUCINE | |
HK1213463A1 (zh) | 具有變化截面的支架 | |
GB201309274D0 (en) | Treatment Of Fuel | |
PL2872673T3 (pl) | Niepodzielone ogniwo elektrolityczne i jego zastosowanie | |
SG11201404195YA (en) | Coprocessing of biofeeds with group vi metal catalysts | |
GB201223374D0 (en) | Personal care composition and methods of making the same | |
HK1198587A1 (en) | Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2- | |
ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
HK1207154A1 (en) | C1q-adiponectin complex and use thereof c1q- | |
HK1209033A1 (zh) | 奧地帕西在治療黏多醣症病中的應用 | |
ZA201502159B (en) | Mycobacterial thiolperoxidase and its use | |
GB201215414D0 (en) | Composition and use | |
EP2820344A4 (en) | HUB AND CONNECTOR ASSEMBLY | |
HUP1200620A2 (en) | Bio honey product with different stability | |
GB201222541D0 (en) | Kiddibidet and pottibidet |